What Do Brokerages Say About Cipla After Its Q2 Results?
About the Company
Cipla Ltd is one of India’s largest pharmaceutical companies, with a global presence spanning over 80 countries. Known for its respiratory, antiretroviral, and chronic therapy portfolio, Cipla continues to strengthen its U.S. generics business while expanding across emerging markets. The company’s focus remains on sustainable growth through product innovation and cost control.
Q2 FY26 Performance Summary
| Metric | Q2 FY26 | Q2 FY25 | YoY Change |
|---|---|---|---|
| Revenue | ₹7,589 Cr | ₹7,051 Cr | +8% |
| EBITDA | ₹1,894 Cr | ₹1,885 Cr | +0.5% |
| EBITDA Margin | 24.97% | 26.75% | -178 bps |
| Net Profit | ₹1,351 Cr | ₹1,302 Cr | +4% |
Brokerage Views and Price Targets
| Brokerage | Rating | Target Price (₹) | Key Highlights |
|---|---|---|---|
| Citi | Buy | 1,800 | Sees multiple margin levers in FY27; strong non-US growth. |
| Jefferies | Hold | 1,690 | FY26 margin cut by 50–75 bps due to higher R&D spend. |
| Goldman Sachs | Sell | 1,425 | Margins below estimate; rising R&D and slower US growth. |
| Morgan Stanley | Underweight | 1,396 | Muted FY25–28 EPS CAGR; near-term slowdown expected. |
Peer Comparison
| Company | P/E (TTM) | ROE (%) | Debt/Equity |
|---|---|---|---|
| Cipla | 27.4x | 17.1% | 0.09 |
| Sun Pharma | 34.8x | 18.9% | 0.06 |
| Dr. Reddy’s Labs | 23.1x | 21.5% | 0.07 |
| Lupin | 42.0x | 14.8% | 0.28 |
SWOT Analysis
| Strengths | Weaknesses | Opportunities | Threats |
|---|---|---|---|
| Strong domestic brand recall and robust chronic portfolio. | US sales pressure and slower ramp-up of new launches. | Product diversification into respiratory and oncology therapies. | Regulatory challenges and rising competition in generics. |
Investment Verdict
Short Term: Neutral; limited catalysts in the near term.
Medium Term: Positive; margin recovery and new approvals in FY27 could drive re-rating.
Long Term: Attractive; strong domestic franchise and leadership in chronic therapies ensure stability and growth.
Investor Takeaway
Cipla’s fundamentals remain strong despite temporary margin compression. Broader product expansion and steady demand across India and emerging markets provide long-term confidence. Traders should await clear margin stabilization before accumulating positions for FY27.
For more research-backed insights, visit Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions.
